{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:48:42Z","timestamp":1767905322770,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jfo.2024.104169","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T13:16:59Z","timestamp":1717507019000},"page":"104169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA)"],"prefix":"10.1016","volume":"47","author":[{"given":"L.","family":"El Fekih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Khairallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ben Amor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-3081","authenticated-orcid":false,"given":"A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Chiambaretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Messaoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2024.104169_bib0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/aos.13436","article-title":"Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting","volume":"96","author":"Baudouin","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0215","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2024.104169_bib0220","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The pathophysiology of dry eye disease: what we know and future directions for research","volume":"124","author":"Pflugfelder","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104169_bib0225","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2024.104169_bib0230","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/bjophthalmol-2019-315747","article-title":"Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review","volume":"105","author":"Aragona","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.survophthal.2009.02.002","article-title":"Topical ophthalmic cyclosporine: pharmacology and clinical uses","volume":"54","author":"Donnenfeld","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0240","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/14656566.2017.1372748","article-title":"Lifitegrast for the treatment of dry eye disease in adults","volume":"18","author":"Donnenfeld","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jfo.2024.104169_bib0245","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","article-title":"Evaluation of topical cyclosporine for the treatment of dry eye disease","volume":"126","author":"Perry","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0250","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104169_bib0255","first-page":"1356","article-title":"Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes","volume":"41","author":"Brignole","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2024.104169_bib0260","first-page":"3493","article-title":"Sj\u00f6gren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium","volume":"35","author":"Jones","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2024.104169_bib0265","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered cytokine balance in the tear fluid and conjunctiva of patients with Sj\u00f6gren's syndrome keratoconjunctivitis sicca","volume":"19","author":"Pflugfelder","year":"2009","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jfo.2024.104169_bib0270","first-page":"2283","article-title":"Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease","volume":"42","author":"Solomon","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2024.104169_bib0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajo.2015.04.008","article-title":"Effects of dry eye therapies on environmentally induced ocular surface disease","volume":"160","author":"Moore","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajo.2003.10.036","article-title":"Antiinflammatory therapy for dry eye","volume":"137","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0285","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","article-title":"Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj\u00f6gren syndrome","volume":"106","author":"Marsh","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104169_bib0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","article-title":"Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial","volume":"123","author":"Pinto-Fraga","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104169_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5301\/ejo.5000836","article-title":"A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome","volume":"27","author":"Chiambaretta","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0300","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/03007995.2018.1434496","article-title":"Comparison of the effect of a hyaluronate-trehalose solution to hyaluronate alone on ocular surface disease index in patients with moderate to severe dry eye disease","volume":"34","author":"Doan","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jfo.2024.104169_bib0305","first-page":"595","article-title":"A randomized crossover study comparing trehalose\/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome","volume":"11","author":"Pinto-Bonilla","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jfo.2024.104169_bib0310","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/ICO.0000000000000358","article-title":"Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease","volume":"34","author":"Schmidl","year":"2015","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2024.104169_bib0315","first-page":"676","article-title":"\u00c9tude d\u2019un peptide (sel de magnesium de l\u2019acide N-acetyl (alpha-beta)-aspartyl-glutamique). Mise en evidence de la protection contre les destructions cellulaires locales provoquees par l\u2019activation in situ du complement","volume":"17","author":"Chevance","year":"1986","journal-title":"J Pharmacol"},{"key":"10.1016\/j.jfo.2024.104169_bib0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF01968092","article-title":"In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA)","volume":"24","author":"Etievant","year":"1988","journal-title":"Agents Actions"},{"key":"10.1016\/j.jfo.2024.104169_bib0325","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01980896","article-title":"Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA)","volume":"32","author":"Feuillard","year":"1991","journal-title":"Agents Actions"},{"key":"10.1016\/j.jfo.2024.104169_bib0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/09273949709085045","article-title":"Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells","volume":"5","author":"Goldschmidt","year":"1997","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2024.104169_bib0335","first-page":"319","article-title":"Pharmacological modulation of histamine release from choroidal mast cells induced by N-acetyl-aspartil-glutamic acid (MgNAAGA)","volume":"42","author":"Secchi","year":"1987","journal-title":"Farmaco Prat"},{"key":"10.1016\/j.jfo.2024.104169_bib0340","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1398-9995.1990.tb00512.x","article-title":"Effects of N-acetyl-aspartyl glutamic acid and sodium cromoglycate on leukotriene B4 secretion by human leukocytes","volume":"45","author":"Goldschmidt","year":"1990","journal-title":"Allergy"},{"key":"10.1016\/j.jfo.2024.104169_bib0345","first-page":"273","article-title":"Effect of N-acetyl-aspartyl-glutamate (Naaga) on in-vitro leukotriene synthesis by macrophage cell line P388D1","volume":"12","author":"Jambou","year":"1990","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.jfo.2024.104169_bib0350","first-page":"993","article-title":"Effets inhibiteurs du dipeptide N-ac\u00e9tyl-aspartyl-glutamate (NAAGA) sur l\u2019adh\u00e9rence des leucocytes humains aux cellules endoth\u00e9liales activ\u00e9es et l\u2019expression des mol\u00e9cules d\u2019adh\u00e9sion CD11b, CD49d, ICAM-1, ICAM-2, VCAM-1 et ELAM-1","volume":"25","author":"Bouhlal","year":"2002","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0355","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jfo.2009.09.006","article-title":"Evaluation de l\u2019efficacite du NAAGA dans la secheresse oculaire","volume":"32","author":"Brignole-Baudouin","year":"2009","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0360","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s00417-022-05682-x","article-title":"Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients","volume":"260","author":"Shin","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0365","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0370","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1755-3768.1991.tb02064.x","article-title":"Conjunctival hyperaemia in non-contact lens wearers","volume":"69","author":"McMonnies","year":"1991","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0375","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2024.104169_bib0380","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OPTH.S1496","article-title":"The challenge of dry eye diagnosis","volume":"2","author":"Savini","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0385","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/archopht.1969.00990020012003","article-title":"Diagnostic tests in the sicca syndrome","volume":"82","author":"van Bijsterveld","year":"1969","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0390","first-page":"328","article-title":"Effet modulateurs de collyres anti-allergiques sur l\u2019activation du compl\u00e9ment induite in vitro par des polluants particulaires","volume":"26","author":"Blondin","year":"2003","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0395","first-page":"357","article-title":"Inhibition of anaphylactic release of leukotrienes by magnesium N-acetyl aspartyl glutamate (NAAGA)","volume":"1","author":"Bastide","year":"1987","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jfo.2024.104169_bib0400","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2020.03.044","article-title":"Patient-reported burden of dry eye disease in the United States: results of an online cross-sectional survey","volume":"216","author":"Dana","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0405","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","article-title":"Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life","volume":"157","author":"Paulsen","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104169_bib0410","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","article-title":"Dry eye disease: impact on quality of life and vision","volume":"1","author":"Uchino","year":"2013","journal-title":"Curr Ophthalmol Rep"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:22:07Z","timestamp":1726154527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551224001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0181551224001141"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104169","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA)","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104169"}}